Walk down the "longevity" aisle of any research-compound catalog and you will find a handful of molecules filed together as if they did the same job. They do not. The longevity label is a marketing convenience, not a mechanism. It groups compounds by an aspiration—slowing or reversing some aspect of biological aging—while hiding the fact that each member is chasing a completely different theory of why organisms age in the first place.
Aging research has spent the last decade organizing itself around a framework often called the hallmarks of aging: a short list of interconnected biological processes—telomere attrition, mitochondrial dysfunction, cellular senescence, immunosenescence, deregulated nutrient sensing, and others—that together drive the aging phenotype. It is the single most useful lens for reading the longevity shelf, because most catalog compounds map onto exactly one hallmark. Understanding which one tells you far more than the shared "anti-aging" tag ever could.
This primer walks the Trulogic Labs longevity category and sorts its members by the hallmark each is investigated against. As always, these are research compounds, not therapies, and the evidence base for most is preclinical.
Telomere Attrition: Epithalon
The oldest and most-studied member of the category is Epithalon, a four–amino-acid peptide (Ala-Glu-Asp-Gly, or AEDG) derived from research on pineal-gland extracts. Its associated hypothesis targets telomere attrition—the progressive shortening of the protective caps on chromosomes that occurs with each cell division.
The proposed mechanism is induction of telomerase, the enzyme (specifically its catalytic subunit, hTERT) that rebuilds telomeric DNA. Preclinical work from a single primary research lineage has reported telomerase activation and extended cell-division capacity in cultured cells, alongside a separate strand of research on circadian and melatonin-related signaling tied to the peptide's pineal origin.
The important caveats for anyone reading this literature: the telomerase story rests heavily on one research group and has not been broadly replicated, telomere length is a biomarker rather than a proven longevity endpoint, and telomerase activation intersects with cancer biology, which is exactly why the field treats aggressive telomere-lengthening claims with caution. Epithalon is best understood as a probe for the telomere hypothesis, not a validated intervention.
Mitochondrial Dysfunction: SS-31 and NAD+
Two catalog items attack the same hallmark—mitochondrial dysfunction, the age-related decline in the cell's energy-producing machinery—from opposite ends.
SS-31 (also known by its clinical development name elamipretide) is an aromatic-cationic tetrapeptide from the Szeto-Schiller peptide series. Its distinguishing feature is that it concentrates in the inner mitochondrial membrane and binds cardiolipin, a phospholipid essential to the integrity of the electron transport chain. By stabilizing cardiolipin, the peptide is investigated for its effects on mitochondrial efficiency and reactive-oxygen-species production. Notably, elamipretide has advanced further into human clinical study than most compounds on this shelf, appearing in trials for primary mitochondrial myopathy and rare cardiolipin-related disorders—making it one of the few longevity-adjacent peptides with meaningful clinical-stage data, even though a broad anti-aging indication is not established.
NAD+ approaches the same hallmark chemically rather than structurally. It is worth being precise here: NAD+ is not a peptide at all—it is a dinucleotide coenzyme central to cellular redox reactions and a required substrate for the sirtuin and PARP enzyme families. Cellular NAD+ levels are widely reported to decline with age, and the research interest lies in whether replenishing the pool restores sirtuin-mediated signaling and mitochondrial function. It sits in the longevity category because of that biology, not because it shares a chemical class with the peptides around it—a good example of why reading the catalog by mechanism beats reading it by shelf label.
Cellular Senescence: FOXO4-DRI
FOXO4-DRI targets a different hallmark entirely: cellular senescence, the accumulation of "zombie" cells that have stopped dividing but refuse to die and instead secrete inflammatory signals into surrounding tissue.
FOXO4-DRI is a senolytic—a compound designed to selectively eliminate senescent cells. It is a retro-inverso peptide engineered to disrupt the interaction between the FOXO4 protein and p53. In senescent cells, that interaction helps keep the cell alive despite accumulated damage; disrupting it is reported to push those cells into apoptosis while sparing healthy cells. The foundational preclinical work (Baar and colleagues, published in Cell in 2017) demonstrated senescent-cell clearance and functional improvements in aged mouse models. This is a mechanistically elegant and much-cited proof of concept, but it remains preclinical, and senolytic peptide research broadly is still early relative to the small-molecule senolytics being tested elsewhere.
Immunosenescence: Thymalin
The final major mechanism on the shelf is immunosenescence—the age-related decline of the immune system, driven substantially by involution (shrinkage) of the thymus, the organ where T-cells mature.
Thymalin is a peptide preparation historically derived from thymic tissue, studied for its capacity to modulate and restore T-cell-related immune function in aging models. It comes from the same long-running Russian gerontology research tradition as Epithalon, and much of its literature emphasizes immune-parameter normalization in older subjects. As with Epithalon, the evidence concentration within a single research lineage is the main caveat a careful reader should keep in mind. It sits adjacent to the immune-category compound Thymosin Alpha-1, and the two are often confused despite different origins and research profiles.
Why the Mechanism Map Matters
Sorting the shelf this way produces an immediately useful picture:
- Epithalon → telomere attrition (telomerase hypothesis, single-lineage, unreplicated)
- SS-31 / elamipretide → mitochondrial dysfunction, structural (cardiolipin; clinical-stage data)
- NAD+ → mitochondrial/metabolic, biochemical (sirtuin substrate; not a peptide)
- FOXO4-DRI → cellular senescence (senolytic; strong preclinical proof of concept)
- Thymalin → immunosenescence (thymic/immune restoration; single-lineage)
Three consequences follow. First, these compounds are not interchangeable—a researcher modeling telomere biology and one modeling senescent-cell burden are studying different hallmarks with different readouts. Second, the evidence maturity varies enormously across the shelf, from clinical-stage (elamipretide) to influential-but-preclinical (FOXO4-DRI) to single-lineage-and-unreplicated (Epithalon, Thymalin). Third, the hallmarks are interconnected in the underlying biology, which is why some research programs explore combinations—but that interconnection is a hypothesis to be tested, not a license to assume additive benefit.
The honest summary of the longevity category is that it is a collection of interesting mechanistic probes at very different stages of validation, not a validated toolkit. That is exactly the framing the research literature supports, and it is the reason mechanism-first reading beats category labels every time. For more on evaluating compound quality and documentation, see our quality standards and research library.
FAQ
Are longevity peptides proven to extend lifespan in humans? No. No compound in this category has demonstrated human lifespan extension. The evidence ranges from clinical-stage safety and efficacy data for specific rare-disease indications (elamipretide) to preclinical animal and cell studies. All are sold for research use only.
Why is NAD+ grouped with peptides if it isn't one? Catalogs organize by research application, not strictly by chemical class. NAD+ is a coenzyme, not a peptide, but its role in age-related mitochondrial and sirtuin biology places it alongside longevity peptides in most reference libraries. The chemistry is worth knowing precisely.
What is a "hallmark of aging"? It is one of a defined set of interconnected biological processes—telomere attrition, mitochondrial dysfunction, cellular senescence, immunosenescence, and others—that aging researchers use as a framework for the drivers of biological aging. Most longevity compounds are studied against one specific hallmark.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.